臨床泌尿器科66巻1号

2012年01月発行

特集 進行性腎癌に対する分子標的治療薬・薬剤選択ガイド

進行性腎細胞癌の新たな分子標的はあるか？

著者： 加藤琢磨¹ 筧善行¹

所属機関： ¹香川大学医学部泌尿器科

ページ範囲：P.69 - P.74

要旨　腎細胞癌に対する分子標的治療薬として，sorafenib，sunitinib，temsirolimus，everolimus，pazopanib（日本未承認），bevacizumab（日本未承認）が現在臨床で使用されている。しかしながら，サイトカイン療法を凌ぐ治療成績を示す一方で，非特異的な性質に伴う多彩なoff-target effectも問題となっている。off-target effectは減量や休薬の原因となり，また，治療薬ごとにoff-target effectがover rapすることが，combination therapyの薬剤選択の制限となっている。これらの問題を克服すべく，VEGFRに高い選択性と低いoff-targeted toxicitiesを示す薬剤の開発が進んでいる。本稿では，第Ⅱ相あるいは第Ⅲ相試験が進行中の有望な新規分子標的治療薬とその臨床成績を紹介する。

参考文献

1）Schmidinger M and Bellmunt J：Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev 36：416-424, 2010

2）Négrier S and Raymond E：Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. Invest New Drugs. 2011 May 15.［Epub ahead of print］

3）Ellis LM and Hicklin DJ：VEGF-targeted therapy：mechanisms of anti-tumour activity. Nat Rev Cancer 8：579-591, 2008

4）荒尾徳三，西尾和人：VEGF　血管内皮細胞増殖因子．がんの分子標的と治療薬事典．西尾和人，西條長宏（編）．羊土社，東京，pp68-69，2010

5）藤田直也：AKT PKB．がんの分子標的と治療薬事典．西尾和人，西條長宏（編）．羊土社，東京，pp46-47，2010

6）藤田直也：mTOR哺乳類のラパマイシン標的タンパク質．がんの分子標的と治療薬事典．西尾和人，西條長宏（編）．羊土社，東京，pp48-49，2010

7）Bhargava P and Robinson MO：Development of second-generation VEGFR tyrosine kinase inhibitors：current status. Curr Oncol Rep 13：103-111, 2011

8）Fisher R, Pickering L and Larkin J：New targeted therapies for renal cell carcinoma. Expert Opin Investig Drugs 20：933-945, 2011

9）Sternberg CN, Davis ID, Mardiak J, et al：Pazopanib in locally advanced or metastatic renal cell carcinoma：results of a randomized phase Ⅲ trial. J Clin Oncol 28：1061-1068, 2010

10）Hu-Lowe DD, Zou HY, Grazzini ML, et al：Nonclinical antiangiogenesis and antitumor activities of axitinib（AG-013736）, an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14：7272-7283, 2008

11）Rixe O, Bukowski RM, Michaelson MD, et al：Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer：a phase Ⅱ study. Lancet Oncol 8：975-984, 2007

12）Rini BI, Wilding G, Hudes G, et al：Phase Ⅱ study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27：4462-4468, 2009

13）Rixe O, Dutcher J, Motzer R, et al：Diastolic blood pressure and pharmacokinetics as predictors of axitinib efficacy in metastatic renal cell cancer. J Clin Oncol 27：Abstract 5045, 2009

14）Bhargava P, Esteves B, Al-Adhami M, et al：Activity of tivozanib（AV-951）in patients with renal cell carcinoma：subgroup analysis from a phase Ⅱ randomized discontinuation trial. J Clin Oncol 28：Abstsact 4599, 2010

15）Bhargava P, Esteves B, Al-Adhami M, et al：Effect of hypertension, nephrectomy, and prior treatment on the efficacy of tivozanib（AV-951）in a phase Ⅱ randomized discontinuation trial in patients with renal cell carcinoma. abstract 342. Presented at the American Society of Clinical Oncology（ASCO）Genitourinary Cancers Symposium, San Francisco, CA；March 5-7, 2010

16）Kabbinavar FF, Srinivas S, Hauke RJ, et al：Results from a phase Ⅰ trial of tivozanib（AV-951）combined with temsirolimus therapy in patients with renal cell carcinoma. J Clin Oncol 29：abstract 4549, 2011

17）Drevs J, Siegert P, Medinger M, et al：Phase Ⅰ clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25：3045-3054, 2007

18）Mulders P, Nathan P, Hawkins R, et al：Final results of a phase Ⅱ randomised study of cediranib（RECENTIN）in patients with advanced renal cell carcinoma. Eur J Cancer 7：abstract 49LBA, 2009

19）Angevin E, Lopez JA, Pande A, et al：TKI258（dovitinib lactate）in metastatic renal cell carcinoma patients refractory to approved targeted therapies：a phase Ⅰ/Ⅱ dose finding and biomarker study. J Clin Oncol 27：abstract 3563, 2009

20）Angevin E, Grünwald V and Ravaud A：A phase Ⅱ study of dovitinib（TKI258）, an FGFR-and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer. J Clin Oncol 29：abstract 4551, 2011

21）Wong CI, Koh TS, Soo R, et al：Phase Ⅰ and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 27：4718-4726, 2009

22）Tannir NM, Wong Y, Kollmannsberger CK, et al：Phase Ⅱ trial of linifanib in patients with advanced renal cell cancer after sunitinib failure. J Clin Oncol 28：abstract 4527, 2010

23）Singer EA, Gupta GN and Srinivasan R：Update on targeted therapies for clear cell renal cell carcinoma. Curr Opin Oncol 23：283-289, 2011

24）福原茂朋，望月直樹：アンジオポエチン-1による血管安定化メカニズム．日薬理誌 136：26-30，2010

25）Eisen T, Nathan P, Joensuu H, et al：Phase Ⅱ trial of the oral multikinase inhibitor BAY 73-4506 as 1st-line therapy in patients with metastatic or unresectable renal cell carcinoma（RCC）. Eur J Cancer Suppl 2009b；7：abstract 7.105

26）藤田直也：PI3K/Akt生存増殖シグナル伝達経路を標的とした分子標的治療薬開発の現状．秒進分歩する癌研究と分子標的治療．原　英二，平尾　敦，矢野聖二，他（編）．羊土社，東京，pp166-172，2011

27）Cho DC, Figlin RA, Flaherty KT, et al：A phase Ⅱ trial of perifosine in patients with advanced renal cell carcinoma who have failed tyrosine kinase inhibitors. J Clin Oncol 27：abstract 5101, 2009

28）Vogelzang NJ, Hutson TE, Samlowski W, et al：Phase Ⅱ study of perifosine in metastatic renal cell carcinoma（RCC）progressing after prior therapy（Rx）with a VEGF receptor inhibitor. J Clin Oncol 27：abstract 5034, 2009